Improved early-stage diagnosis of pancreatic cancer offers a major opportunity to improve overall survival, Immunovia AB, Lund Sweden
Pancreatic cancer (PC) has one of the worst survival rates of the most common cancers with only 4-6% surviving five years after they are diagnosed. The mortality is expected to increase further over the coming years. PC thus remains a highly fatal disease. Today, complete surgical resection (removal of the pancreas) is the only potentially curative modality of treatment available. Detecting PC lesions early enough to perform this procedure is, however beset with difficulties.
Nevertheless, the timeline of progression from low grade precursor lesions to invasive cancer does offer a window of opportunity to detect the disease earlier than it is currently possible. This is turn, should radically improve overall survival in PC by making far more patients eligible for resection. By providing physicians with actionable information early enough for the cancer to be removed surgically, the overall 5 year PC patient survival rate could increase from 4-6% to approximately 60%.
This white paper presents IMMray™ PanCan-d, a blood test developed for early stage diagnosis of pancreatic cancer. Based on recent results from retrospective studies, that are now under publication, IMMray™ PanCan-d is able to differentiate with 96% accuracy the early resectable stages of pancreatic cancer, stage I and II, from the healthy controls.
When analyzing all stages of pancreatic cancer in retrospective studies covering more than 3000 blood samples, the accuracy of IMMray™ PanCan-d is reported as high as 98%. To complete the validation of the test, Immunovia plans to perform additional retrospective studies and implement a prospective study involving 1000 risk group individuals at several different centers in the US and Europe.
Immunovia’s in-house skills are outlined in the white paper with particular focus on the antibody microarray production and the test methodology to derive unique serum biomarker signatures through state-of-the-art bioinformatics algorithms and software. Immunovia’s own laboratory service for IMMray™ PanCan-d testing, that is currently undergoing accreditation, is introduced in this paper for the first time.
As IMMray™, creates a biological snapshot of an individual’s immune response by analysing serum proteins that change as a sign of disease, the white paper describes the partnership opportunities not only for early diagnosis, but also for following disease progression, therapy monitoring and patient classification, both for cancers and autoimmune diseases.
Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. Shimizu Y et al. J Gastroenterol Hepatol. 2005 Oct;20(10):1591-4.